Effect of Transdermal Testosterone or Alpha-Lipoic Acid on Erectile Dysfunction and Quality of Life in Patients with Type 2 Diabetes Mellitus / Эффект применения трансдермального тестостерона или альфа-ли- поевой кислоты на эректильную дисфункцию и качество жизни пациентов со сахарным диабетом типа 2

Mitkov, M; Aleksandrova, I. Ya.; Orbetzova, Maria

doi:10.2478/folmed-2013-0006

Cited by 22 publications

(6 citation statements)

References 19 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ED prevalence in diabetic men is 28–75%, rising with patient’s age and duration of diabetes (15). In addition, reports showed that ALA, the second component of nanospheres matrix and antioxidant agent, improved flow-mediated vasodilation in prediabetics and has a role in improving ED 9 . Reduction of glutathione (natural antioxidant) levels by aging can cause relaxation of penile arteries.…”

Section: Resultsmentioning

confidence: 99%

“…ALA restores vitamin E and vitamin C levels and prevents certain kinds of cell damage in the body. ALA has shown significant improved sexual function and quality of life in both animals and human investigations 6 – 9 . Previous reports showed the potential use of ALA in the treatment of diabetic impotence through prevention of corpus cavernosum dysfunction 10 , 11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil

Ahmed

2018

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to utilize the biocompatibility of the natural ingredients zein and alpha lipoic acid (ALA) as a novel nanosphere matrix formulation that encapsulates vardenafil (VRD) for improved drug delivery and bioavailability. Three formulations were prepared using zein: ALA ratio of 1:1, 2:1 and 3:1 by liquid–liquid phase separation method. Physicochemical characterization and in vitro diffusion evaluation were carried out for the prepared formulations. A single dose clinical pharmacokinetic study was carried out for the selected formulation. Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively. Single dose clinical pharmacokinetic results, in healthy human volunteers, showed improved VRD bioavailability by 2.5 folds from nanosphere formula (F3) compared with the marketed tablets. The formulation of novel zein-ALA nanospheres offers the possibility for application of a biocompatible nano-carrier system in drug delivery for improved drug delivery and efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil

Ahmed

2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Schiavi et al's 1997 study (Schiavi, R. C., White, D., Mandeli, J., & Levine, 1997), one of the earliest investigations, demonstrated that TTh enhanced ejaculatory function when compared to non-Treatment (non-T) options. Additionally, two more recent studies by Mitkov et al in 2013and Brock et al in 2016(Mitkov, Aleksandrova, & Orbetzova, 2013Brock, G., 2016) found improvements in overall orgasmic function associated with TTh. However, contrasting results were observed in other studies conducted by Buvat et al in 2011 andPaduch et al in 2015, where no significant enhancements in orgasmic or ejaculatory parameters were noted with TTh in comparison to non-T treatment (Pignanelli et al, 2023).…”

Section: Testosterone Therapy In Overall Sexual Dysfunctionmentioning

confidence: 95%

Unveiling The Effect of Testosterone Therapy on Sexual Dysfunction

Gede Pradipta Mahardika Wijaya,

Agung Thede Surya Putra,

Gede Sanjaya

2024

JOSR

View full text Add to dashboard Cite

Male sexual dysfunction, including ED, PD, and PE, is prevalent, particularly in older men. Research has suggested that hormonal factors, specifically low total testosterone levels, may contribute to these conditions. TTh has been explored as a potential treatment for male sexual dysfunction, but studies have used varying assessment methods. This meta-analysis aimed to provide a comprehensive evaluation by using a consistent assessment tool, the International Index of Erectile Function (IIEF). Methods: Randomized controlled trials (RCTs) comparing TTh with placebo in adult men with sexual dysfunction were included. The primary outcome measure was the IIEF score. Studies were selected through a systematic literature search, and 16 RCTs met the inclusion criteria. Results: 16 studies were deemed from 98 studies was identified. The effect size testosterone therapy (Tth) in overall sexual dysfuction with standardized mean difference (SMD) 1.8, 95% CI 0.31 to 3.43. Impact of testosterone therapy on erectile dysfunction with Mean Difference (MD) 3.07, 95% CI 1.68 to 4.46. P-value 0.0001) (p<0.0001). Discussion: Testosterone plays a crucial role in regulating various aspects of male health, including sexual function. TTh has demonstrated positive effects on sexual function, particularly in improving erectile function. The time course of TTh effects suggests that improvements in libido and sexual activity can occur within weeks, while substantial improvements in erectile function may take several months. Additional assessment tools, such as the PDQ-Q4 and DISF-M-II, have also shown positive outcomes with TTh.

show abstract

“…The basic science literature has confirmed the necessity of androgens to generate adequate intracavernosal pressures and smooth muscle function to obtain an erection [59]. The literature showing the impact of testosterone replacement therapy (TRT) on erectile function is quite heterogenous (Table 1) [6061626364656667686970717273747576777879808182838485868788899091]. A subset analysis of the Olmstead County Cohort published by Gades et al [92] showed that testosterone has a statistically significant positive correlation with erectile function, even when adjusted for age.…”

Section: Hypogonadismmentioning

confidence: 99%

Modifying Risk Factors in the Management of Erectile Dysfunction: A Review

DeLay

Haney

Hellstrom

2016

World J Mens Health

View full text Add to dashboard Cite

Erectile dysfunction (ED) is prevalent among men and its presence is often an indicator of systemic disease. Risk factors for ED include cardiovascular disease, hypertension, diabetes mellitus (DM), tobacco use, hyperlipidemia, hypogonadism, lower urinary tract symptoms, metabolic syndrome, and depression. Addressing the modifiable risk factors frequently improves a patient's overall health and increases lifespan. The literature suggests that smoking cessation, treatment of hyperlipidemia, and increasing physical activity will improve erectile function in many patients. How the treatment of DM, depression, and hypogonadism impacts erectile function is less clear. Clinicians need to be aware that certain antihypertensive agents can adversely impact erectile function. The treatment of men with ED needs to address the underlying risk factors to ameliorate the disease process.

show abstract

Cited by 22 publications

References 19 publications

Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil

Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil

Unveiling The Effect of Testosterone Therapy on Sexual Dysfunction

Modifying Risk Factors in the Management of Erectile Dysfunction: A Review

Contact Info

Product

Resources

About